Niranjan Kanesa-Thasan - 10 Feb 2022 Form 4 Insider Report for Icosavax, Inc.

Role: Chief Medical Officer
Signature: /s/ Elizabeth Bekiroglu, Attorney-in-Fact for Niranjan Kanesa-Thasan
Issuer symbol: N/A
Transactions as of: 10 Feb 2022
Net transactions value: $0
Form type: 4
Filing time: 14 Feb 2022, 18:06:21 UTC
Previous filing: 04 Feb 2022
Next filing: 14 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ICVX	Common Stock	Award	$0	+19,485	+8.7%	$0.000000	242,559	10 Feb 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ICVX	Stock Option	Award	$0	+81,950		$0.000000	81,950	10 Feb 2022	Common Stock	81,950	$17.55	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs") which will vest as to 25% of the total number of RSUs granted on each of the first four anniversaries of February 10, 2022, subject to the reporting persons continued service through the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer and the RSUs have no expiration date.
F2	Includes 1,666 shares acquired under the Issuer's employee stock purchase plan on November 30, 2021.
F3	25% of the shares subject to the option will vest on February 10, 2023, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the reporting person's continued service through the applicable vesting date.